Form 4: Cryoport Director Robert J. Hariri Reports Significant Equity and Option Grants

Cryoport, Inc. Director Robert J. Hariri has reported the acquisition of 23,214 restricted stock rights and 41,098 stock options, increasing his beneficial ownership in the company.

Summary

• Robert J. Hariri, a Director of Cryoport, Inc. (CYRX), reported changes in his beneficial ownership of company securities via a Form 4 filing.
• On June 6, 2025, Mr. Hariri acquired 23,214 restricted stock rights at a price of $0 per share. These rights are scheduled to vest in full on June 6, 2026, and will automatically convert to shares of common stock on a one-for-one basis upon vesting.
• Additionally, on June 6, 2025, Mr. Hariri acquired 41,098 options to buy common stock with an exercise price of $7 per share. These options will vest monthly, with 1/12th vesting on the 6th of each month beginning July 6, 2025, and are set to expire on June 6, 2032.
• Following these transactions, Mr. Hariri's direct beneficial ownership of common stock is reported as 31,275 shares, and he directly holds 41,098 options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates an insider receiving equity grants, which aligns their interests with shareholders and is a common form of long-term incentive. There are no negative disclosures or adverse events reported.

Positives

• A Director, Robert J. Hariri, has been granted additional equity (restricted stock rights and options), which aligns his interests with long-term shareholder value.
• The acquisition of 23,214 restricted stock rights and 41,098 options indicates continued commitment and incentivization of key management.

Negatives

• The document does not contain any explicitly negative information.

Risks

• The value of the granted restricted stock and options is subject to the future performance of Cryoport's common stock.
• The options' value is dependent on the stock price exceeding the $7 exercise price, and there is no guarantee of future appreciation.

Future Outlook

The grants of restricted stock and options are forward-looking incentives designed to align the director's interests with the long-term performance and growth of Cryoport, Inc. The vesting schedules extending into 2026 and 2032 indicate a long-term commitment and incentive structure for the director.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director in a publicly traded company. Such grants are common practice across various industries, including the life sciences and logistics sectors where Cryoport operates, to incentivize and retain key personnel by linking their compensation to company performance and long-term value creation.

Comparison to Industry Standards

• Equity grants to directors, including restricted stock and stock options, are a standard component of executive and director compensation packages across publicly traded companies.
• The specific amounts and vesting schedules are typically determined by the company's compensation committee based on factors such as individual performance, company performance, and market benchmarks for similar roles in comparable companies within the life sciences and logistics sectors.
• Without specific details on Cryoport's compensation philosophy or peer group compensation data, a direct quantitative comparison to specific companies or projects is not feasible from this document alone.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially fostering long-term value creation and improved governance.
• Employees: No direct impact on general employees is indicated by this specific filing, as it pertains to director compensation.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing, which focuses on insider stock ownership.

Next Steps

• Monitoring the vesting of the restricted stock rights on June 6, 2026, which will convert into common stock.
• Observing the monthly vesting of the stock options, which commenced on July 6, 2025.
• Reviewing any future Form 4 filings by Robert J. Hariri or other Cryoport insiders for further changes in beneficial ownership.

Key Dates

Keywords

Cryoport, CYRX, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock, Beneficial Ownership, Director Compensation, Equity Grant